Syngene is an integrated research, development, and manufacturing organization providing scientific services from early discovery to commercial supply. Our services cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical companies. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 5,200+ scientists and supported by state-of-the-art infrastructure and market-leading technology.
We offer clients customized, end-to-end solutions to fulfill their R&D and manufacturing requirements. This is underpinned by a well-established safety framework, a track record of quality and compliance, and a robust supply chain. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations due to our shared interest in science and commitment to project delivery.
We recognize that trust is built project-by-project. Hence, we pride ourselves on the many deep, long-term client relationships that underpin our business and demonstrate the value of the work we do.
To be a world-class partner delivering innovative scientific solutions
At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges.
At Syngene, we aim to contribute to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges. Here is a quick snapshot of our journey so far
Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry. Prior to joining Syngene in January 2016, he worked with Astrazeneca for over a decade where he has held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India.
Mahesh holds a Ph.D. in Medicinal Chemistry from the University of Utah, the USA, and a bachelor’s degree in Pharmacy from the University of Mumbai. He has 30 years of experience in the biopharmaceutical, vaccine and pharma industries. Mahesh has worked and led different facets of R&D, analytical development, manufacturing and operations, technology transfer, regulatory sciences, quality and capital projects. During a 20-year US stint, he worked with Amgen, Monsanto, Celera Genomics and Molecular Probes (now Thermo Fisher). After moving to India, Mahesh was part of the team that brought WHO prequalification approvals for four vaccines in Biological E. Just before joining Syngene, he was the Chief Operating Officer at Shantha Biotechnics, a Sanofi company, where his responsibilities included operations, quality, supply chain, long-term strategic planning, manufacturing science and technology and human resources. Mahesh is a member of the CII National Committee on Technology, R&D and Innovation. At Syngene, Mahesh is the Chief Operating Officer and a member of the Executive Committee.
Sibaji is a certified Chartered Financial Analyst (CFA) from ICFAI and holds a B.Tech from IIT- Kharagpur. With an MBA from University of Calcutta he has also completed Management Development Programs at Indian Institute of Management (IIM), Ahmedabad and London Business School. He has over 20 years of extensive experience in finance and related functions. His prior experience includes working with Vodafone (Romania), Vodafone (India), Hutchison Essar Limited, Fascel Limited, and the ABP Group. Prior to joining Syngene, he was the CFO and a member of the Board at Vodafone (Romania). At Syngene, he oversees the finance, supply chain, legal, secretarial and IT functions and as a member of the Executive Committee, he plays an important role in driving strategy, improving profitability, identifying new opportunities, improving cash generation and enabling organizational growth.
Andrew holds a Business Studies degree from Blackburn College of Technology, UK, and a professional qualification from the Institute of Personnel Management awarded by Salford Technical College, UK. His broad experience in the Human Resources function includes management of mergers and acquisitions; driving culture change; building a leadership and talent pipeline; and delivering a diversity agenda.
Andrew joined Syngene in December 2022 from management consultancy, Teneo, Hong Kong. Prior to joining Teneo he was CHRO for global retail group, DFS and held HR leadership roles at global biopharmaceutical company, AstraZeneca PLC. He started his career as an HR professional in the UK retail groups House of Fraser and Marks and Spencer PLC. Andrew is a member of the Executive Committee.
Alok holds an M. Tech in Chemical Technology (Food Technology) from Harcourt Butler Technological Institute. He comes with more than 25 years of experience spread across Manufacturing Operations, Quality Assurance, Sustainability/EHS, Production, and Supplier Technical Assurance across varied industries. Over the years, Alok has worked with leading corporates, including Dr. Reddy’s, Reckitt Benckiser, Pepsi Foods Ltd, Godrej Foods, and Beverages Ltd. In his recent assignment as Head of Global Quality Management at Dr. Reddy’s, he harmonized and integrated Quality management systems Globally and was also responsible for quality from all external suppliers and vendors. As Syngene’s CQO, Alok leads the Quality and Compliance function and will be in charge of initiatives to further strengthen our track record in quality and compliance
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas. He has over two decades of experience in the areas of drug discovery for both small and large molecules and has been associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts, providing alliance management for key CRO relationships.
Joydeep is an organic chemist with a Ph.D. from the University of Missouri (USA) and postdoctoral training in medicinal-organic chemistry from the University of Kansas School of Pharmacy (USA). Joydeep has over 30 years of experience in global pharmaceutical companies like Zoetis, Pfizer, Bristol-Myers Squibb, Johnson Matthey Pharmaceuticals, and Ranbaxy at various levels. He has a track record of scientific and leadership contributions to human and animal health drug development programs, including drug discovery and manufacturing in the USA and India. Coupled with his passion for science is his distinctive innovation track record, including patents, publications in peer-reviewed journals, monographs, and technical presentations at international symposia, conferences, and academic institutions.
Alex has three decades of experience in developing, commercializing and life-cycle management of products in various life science industries. Holding positions in both the US and Europe, his experience includes senior roles with global P&L responsibility. Alex was Vice President Operations and Health COO at Johnson Matthey in Greater London in his last assignment. In addition, he has been instrumental in M&A, strategy development and new product introduction.
As a member of the Executive Committee, Alex plays a techno-commercial role, providing technical expertise to the API plant at Mangalore while building a sustainable client base for the business in collaboration with the commercial and business development teams. In addition, Alex is also responsible for biologics operations. Alex is based in Center Valley, Pennsylvania, USA.
Caroline Hempstead has a degree in French studies from Manchester University, UK. She has more than 30 years of experience in Corporate Affairs roles in multinationals in sectors ranging from financial services and oil & gas to pharmaceuticals. She joined Syngene in 2019 as Head of Corporate Affairs. Prior to joining Syngene, she held similar roles at AstraZeneca plc and LafargeHolcim (now Holcim), preceded by leadership roles in corporate communications at Royal Dutch Shell, Inchcape plc and the London Stock Exchange. As a member of the Executive Committee and the ESG Council, her responsibilities encompass corporate communications and Environment, Social and Governance activity.
Ms. Shaw is a first-generation entrepreneur with over 44 years of experience in the field of biotechnology. She is a recipient of ‘Padma Shri’ and the ‘Padma Bhushan’ awards. She was also conferred with the highest French distinction – Chevalier de l’Ordre National de la Légion ’Honneur (Knight of the Legion of Honour) in 2016. She is ranked #1 in the Business Captains category in Global ‘Medicine Maker Power List’ 2018. Ms. Shaw is the only Indian in the Hurun Global Self-Made Women Billionaires List 2017. She is also the Chairperson and Managing Director of Biocon Limited, Independent Director on the Board of Infosys and United Breweries Ltd.
Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry. Prior to joining Syngene in January 2015, he worked with Astrazeneca for over a decade where he has held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India.
Professor Rosenberg received her Diplomed’Ingénieur’ from the Ecole Nationale Superieure des Telecommunications de Bretagne and an M.S. (Computer Science)from the University of California. She also earned a ‘Doctorat en Sciences’ from the Universite de Paris XI. She is a Fellow Member of the Institute of Electrical and Electronics Engineers and was elected a Fellow Member of the Canadian Academy of Engineering in 2013. At present, Prof. Rosenberg is the Canada Research Chair in the Future Internet, the Cisco Research Chair in 5G Systems and a professor in electrical and computer engineering at the University of Waterloo, Canada. At Syngene, Professor Catherine Rosenburg is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.
Mr. Blackburn is a graduate in Management Sciences from Warwick University, United Kingdom, and has a professional accounting qualification from Institute of Cost and Management Accountants, United Kingdom. With more than 40 years experience in the field of finance, he worked as senior finance executive at GlaxoSmithKline, UK. Currently, he is also on the Board of Mereo Biopharma Group Plc. At Syngene, Paul Blackburn is a Chairman of Audit Committee and Risk Management Committee, and a member of Stakeholders Relationship Committee.
Dr. Kuchroo has a doctorate in Pathology from the University of Queensland, Australia. He is also the Samuel L. Wasserstrom Professor of Neurology at the Harvard Medical School, United States, and has 25 patents and over 325 research papers in immunology. He is a Member of the Scientific Advisory Boards of leading pharmaceutical companies including Pfizer, Novartis and GSK. He founded five different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. At Syngene, Dr. Vijay Kuchroo is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.
Ms. Bali is a global business leader with extensive experience in leading large companies both in India and overseas. She served as Chief Executive Officer/ MD of Britannia Industries from 2005 to 2014. Prior to that, she worked with eminent multinationals like The Coca- Cola Company and Cadbury Schweppes Plc in a variety of marketing, general management and chief executive roles across the globe. Ms. Bali serves as an advisory board member of PwC India and is a non-executive director on the boards of Smith & Nephew Plc, Bunge Limited and CRISIL. At Syngene, Vinita Bali is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.
Carl Decicco, Ph.D., has over two decades of experience in the pharmaceutical industry. He has delivered over 140 compounds into development with his teams, several of which have advanced into late-stage clinical testing. Carl retired as the Chief Scientific Officer at Foghorn Therapeutics in Cambridge, MA, in January 2022. Before Foghorn, he was the Head of Discovery at Bristol Myers Squibb (BMS). He is a Partner at Flagship Pioneering and serves on the Board of Cellarity Pharmaceuticals. Carl completed postdoctoral studies with Professor EJ Corey at Harvard University and was a teaching fellow at the University of British Columbia. He obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. At Syngene, Carl is a member of the Risk Management Committee and the Science and Technology Committee.
Ms. Sharmila Abhay Karve is a Fellow member of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with various large and prestigious Indian and multinational clients. She was the first female partner to be elected to the POC and to be appointed as the Chief Ethics Officer. In 2009 she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her assignment as Global Diversity Leader since December 2016, Ms Karve focused her efforts on bringing more diversity throughout the PwC network. At Syngene, Ms. Sharmila Abhay Karve is a member of the Audit Committee and Risk Management Committee and Chairman of the Stakeholders Relationship Committee.
Dr. Parmar holds a BA in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University, and an MD from Harvard Medical School. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco. Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. At Princeton University, Dr. Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. A founding member of the COVID R&D alliance, Dr. Parmar also serves on the Boards of Akouos, Entrada, Homology, Rallybio and Vor Biopharma.
We deliver our services with the highest regard for safety and regulatory compliance. Syngene has certifications from global regulatory authorities for our state-of-the-art facilities and across process and quality management systems.
Syngene is committed to offering various scientific research and development services that meet or exceed client expectations. All our services are in compliance with national and international regulatory requirements.
Syngene considers environment, health, safety & sustainability (EHSS) excellence as a top priority in all of its processes and is fully committed to achieving it in the most responsible manner.
Syngene has world-class infrastructure with more than 1.87 million sq ft. of working space. Syngene strives to attract and retain the best talent in the industry and back them up with world class infrastructure and systems.
We strive towards developing and sustaining healthy and empowered communities by improving the quality of life. We pursue corporate social responsibility with the same passion and responsibility as scientific research.